Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

60 Degrees Pharmaceuticals, Inc.

NASDAQ: SXTP · Life Sciences · 6 alerts · CIK 1946563

Share price
$0.4938Close, Nov 16
Market cap
$2.21M
Shares outstanding
4.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All 60 Degrees Pharmaceuticals, Inc. filings on SEC EDGAR ↗

2:03 PM ET 10-Q
Financial Results

60 Degrees Pharmaceuticals Q3 2026 Results: Net Loss of $2.56M, Loss Widens

60 Degrees Pharmaceuticals reported a net loss of $6.9 million for the nine months ended September 30, 2026, compared to $5.9 million in the prior year period. The company's cash position decreased significantly to $306,191, and management expressed concerns regarding its ability to continue as a going concern without additional financing.

Key figure
Net loss $2.56M
8:23 AM ET 8-K
Capital Raise

60 Degrees Pharmaceuticals Capital Raise of $526K

60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.

Value
$526K
8:06 AM ET 8-K
Clinical Trial Data

60 Degrees Pharmaceuticals Clinical Trial Data

60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.

8:01 AM ET 8-K
Investor Presentation

60 Degrees Pharmaceuticals Investor Presentation

60 Degrees Pharmaceuticals updated its investor presentation for use in meetings with investors and analysts, specifically highlighting progress for Tafenoquine in treating Babesiosis. The presentation was featured at the 2026 ILADS Annual Scientific Conference and outlines a regulatory objective for a potential sNDA submission in 2027.

7:46 AM ET 8-K
Investor Presentation

60 Degrees Pharmaceuticals Investor Presentation

60 Degrees Pharmaceuticals updated its investor presentation and held a webinar to discuss interim data from its clinical study of tafenoquine for severe babesiosis. The presentation covers clinical context, DSMB feedback from the hospital study, and the regulatory path forward for the treatment.

4:06 PM ET 8-K
Business Update

60 Degrees Pharmaceuticals Business Update

60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher (CNPV) for its ARAKODA (tafenoquine) efficacy supplement for babesiosis. The company aims to submit a supplemental New Drug Application (sNDA) in early 2027, potentially making it the first FDA-approved treatment for the tick-borne disease. An interim analysis of its randomized controlled trial is scheduled for October 1, 2026.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.